Annual Report
2022
Sustainability Report
2022
Other reports
Merck KGaA
Darmstadt, Germany
Company
Expertise
Research
News
Careers
Investors
Main menu
Home
To Our Shareholders
To Our Shareholders
Letter from Belén Garijo
The Executive Board
Our Shares
In figures
Management Report
Management Report
Fundamental Information about the Group
Fundamental Information about the Group
The Group
The Group
Life Science
Healthcare
Electronics
Strategy
Strategy
Strategy Fundamentals
Enterprise strategy
Business Strategies
Sustainability Strategy
Strategic finance and dividend policy
Internal Management System
Internal Management System
Key performance indicators
Investments and value management
Capital market-related parameters
Other relevant/
non-financial
performance measures
Research and Development
Research and Development
Life Science
Healthcare
Electronics
Report on Economic Position
Report on Economic Position
Macroeconomic Environment
Review Forecast against Business Developments
Course of Business and Economic Position
Course of Business and Economic Position
Group
Life Science
Healthcare
Electronics
Corporate and Other
Report on Risks and Opportunities
Report on Risks and Opportunities
Business-related risks and opportunities
Financial risks and opportunities
Tax risks
Legal risks
Human resources risks
Information technology risks
Environmental,
climate-related,
and safety risks and opportunities
Management assessment
Report on Expected Developments
Report in accordance with section 315a of the German Commercial Code (HGB)
Non-Financial Statement
Non-Financial Statement
Environmental matters
Environmental matters
Environmental protection
Climate action
Water management
Plant, process and transport safety
Chemical product safety
Employee-related matters
Employee-related matters
Attracting and retaining talent
Diversity, equity and inclusion
Health and safety
Social matters and respect for human rights
Social matters and respect for human rights
Responsible supply chain
Human rights
Patient safety
Prices of medicines
Clinical studies
Bioethics
Digital ethics
Data privacy and cyber security
Anti-corruption and anti-bribery
Anti-corruption and anti-bribery
Compliance management
Interactions with health systems
Other topics
Other topics
Sustainable innovation & technology
Reporting in accordance with the EU Taxonomy Regulation
Compensation Report
Compensation Report
Review of the 2022 fiscal year
Determining the compensation of the Executive Board
Overview of the structure of the compensation system
Executive Board compensation for 2022
Long-Term Incentive Plan (LTIP)
Individual disclosure of the compensation of the Executive Board
Compensation for the Supervisory Board members in fiscal year 2022
Comparative presentation
of compensation and earnings development
Additional Information on Merck KGaA, Darmstadt, Germany, in Accordance with the German Commercial Code (HGB)
Corporate Governance
Corporate Governance
Capital Structure and Corporate Bodies
Statement on Corporate Governance
Statement on Corporate Governance
Corporate governance practices
Procedures of the Executive Board, Supervisory Board, Board of Partners, and its Committees
Promote women in management positions
Diversity policy
Report of the Supervisory Board
Objectives of the Supervisory Board
Consolidated Financial Statements
Consolidated Financial Statements
Income Statement
Statement of Comprehensive Income
Balance Sheet
Cash Flow Statement
Statement of Changes in Net Equity
Notes
Notes
General Disclosures
General Disclosures
1.
Company information
2.
Reporting principles
3.
Discretionary decisions and sources of estimation uncertainty
4.
Subsequent events
Group Structure
Group Structure
5.
Changes in the scope of consolidation
6.
Acquisitions and divestments
7.
Collaboration and licensing agreements
Operating Activities
Operating Activities
8.
Segment Reporting
9.
Net sales
10.
Cost of sales
11.
Marketing and selling expenses
12.
Research and development costs
13.
Other operating income
14.
Other operating expenses
15.
Income tax
16.
Operating cash flow
17.
Earnings per share
Operating Assets, Liabilities, and Contingent Liabilities
Operating Assets, Liabilities, and Contingent Liabilities
18.
Goodwill
19.
Other intangible assets
20.
Property, plant, and equipment
21.
Leasing
22.
Other non-financial assets
23.
Cash flow from investing activities
24.
Inventories
25.
Trade and other receivables
26.
Contract assets
27.
Other provisions
28.
Contingent liabilities
29.
Other non-financial liabilities
30.
Trade and other payables
Employees
Employees
31.
Number of employees
32.
Personnel expenses
33.
Provisions for employee benefits
Capital Structure, Investments, and Financing Activities
Capital Structure, Investments, and Financing Activities
34.
Equity
35.
Cash and cash equivalents
36.
Other financial assets
37.
Financial debt/Capital management
38.
Other financial liabilities
39.
Derivative financial instruments
40.
Finance income and expenses/Net gains and losses from financial instruments
41.
Financing cash flow
42.
Management of financial risks
43.
Information on fair value measurement
44.
Other financial obligations
Other Disclosures
Other Disclosures
45.
Related party disclosures
46.
Executive Board and Supervisory Board compensation
47.
Auditor's fees
Scope of Consolidation
Scope of Consolidation
48.
List of shareholdings
Other Information
Other Information
Responsibility Statement
Reproduction of the Independent Auditor's Report
Business Development 2018 – 2022
Financial Calendar
Annual Report 2022
To Our Shareholders
To Our Shareholders
Letter from Belén Garijo
The Executive Board
Our Shares
In figures
Management Report
Management Report
Fundamental Information about the Group
Fundamental Information about the Group
The Group
The Group
Life Science
Healthcare
Electronics
Strategy
Strategy
Strategy Fundamentals
Enterprise strategy
Business Strategies
Sustainability Strategy
Strategic finance and dividend policy
Internal Management System
Internal Management System
Key performance indicators
Investments and value management
Capital market-related parameters
Other relevant/
non-financial
performance measures
Research and Development
Research and Development
Life Science
Healthcare
Electronics
Report on Economic Position
Report on Economic Position
Macroeconomic Environment
Review Forecast against Business Developments
Course of Business and Economic Position
Course of Business and Economic Position
Group
Life Science
Healthcare
Electronics
Corporate and Other
Report on Risks and Opportunities
Report on Risks and Opportunities
Business-related risks and opportunities
Financial risks and opportunities
Tax risks
Legal risks
Human resources risks
Information technology risks
Environmental,
climate-related,
and safety risks and opportunities
Management assessment
Report on Expected Developments
Report in accordance with section 315a of the German Commercial Code (HGB)
Non-Financial Statement
Non-Financial Statement
Environmental matters
Environmental matters
Environmental protection
Climate action
Water management
Plant, process and transport safety
Chemical product safety
Employee-related matters
Employee-related matters
Attracting and retaining talent
Diversity, equity and inclusion
Health and safety
Social matters and respect for human rights
Social matters and respect for human rights
Responsible supply chain
Human rights
Patient safety
Prices of medicines
Clinical studies
Bioethics
Digital ethics
Data privacy and cyber security
Anti-corruption and anti-bribery
Anti-corruption and anti-bribery
Compliance management
Interactions with health systems
Other topics
Other topics
Sustainable innovation & technology
Reporting in accordance with the EU Taxonomy Regulation
Compensation Report
Compensation Report
Review of the 2022 fiscal year
Determining the compensation of the Executive Board
Overview of the structure of the compensation system
Executive Board compensation for 2022
Long-Term Incentive Plan (LTIP)
Individual disclosure of the compensation of the Executive Board
Compensation for the Supervisory Board members in fiscal year 2022
Comparative presentation
of compensation and earnings development
Additional Information on Merck KGaA, Darmstadt, Germany, in Accordance with the German Commercial Code (HGB)
Corporate Governance
Corporate Governance
Capital Structure and Corporate Bodies
Statement on Corporate Governance
Statement on Corporate Governance
Corporate governance practices
Procedures of the Executive Board, Supervisory Board, Board of Partners, and its Committees
Promote women in management positions
Diversity policy
Report of the Supervisory Board
Objectives of the Supervisory Board
Consolidated Financial Statements
Consolidated Financial Statements
Income Statement
Statement of Comprehensive Income
Balance Sheet
Cash Flow Statement
Statement of Changes in Net Equity
Notes
Notes
General Disclosures
General Disclosures
1.
Company information
2.
Reporting principles
3.
Discretionary decisions and sources of estimation uncertainty
4.
Subsequent events
Group Structure
Group Structure
5.
Changes in the scope of consolidation
6.
Acquisitions and divestments
7.
Collaboration and licensing agreements
Operating Activities
Operating Activities
8.
Segment Reporting
9.
Net sales
10.
Cost of sales
11.
Marketing and selling expenses
12.
Research and development costs
13.
Other operating income
14.
Other operating expenses
15.
Income tax
16.
Operating cash flow
17.
Earnings per share
Operating Assets, Liabilities, and Contingent Liabilities
Operating Assets, Liabilities, and Contingent Liabilities
18.
Goodwill
19.
Other intangible assets
20.
Property, plant, and equipment
21.
Leasing
22.
Other non-financial assets
23.
Cash flow from investing activities
24.
Inventories
25.
Trade and other receivables
26.
Contract assets
27.
Other provisions
28.
Contingent liabilities
29.
Other non-financial liabilities
30.
Trade and other payables
Employees
Employees
31.
Number of employees
32.
Personnel expenses
33.
Provisions for employee benefits
Capital Structure, Investments, and Financing Activities
Capital Structure, Investments, and Financing Activities
34.
Equity
35.
Cash and cash equivalents
36.
Other financial assets
37.
Financial debt/Capital management
38.
Other financial liabilities
39.
Derivative financial instruments
40.
Finance income and expenses/Net gains and losses from financial instruments
41.
Financing cash flow
42.
Management of financial risks
43.
Information on fair value measurement
44.
Other financial obligations
Other Disclosures
Other Disclosures
45.
Related party disclosures
46.
Executive Board and Supervisory Board compensation
47.
Auditor's fees
Scope of Consolidation
Scope of Consolidation
48.
List of shareholdings
Other Information
Other Information
Responsibility Statement
Reproduction of the Independent Auditor's Report
Business Development 2018 – 2022
Financial Calendar
en
Suche
Hauptmenü
Search
Services
Chart Generator
Downloads
Feedback
Share this page:
E-Mail
Facebook
Twitter
LinkedIn